Loading...
WELCOME 2017-11-20T20:36:25+00:00

Significant Regulatory Milestone Towards Phase 2 in Recurrent GBM

July 30th, 2019|0 Comments

FOR IMMEDIATE RELEASE Covington, KY ~ 30 July 2019 Bexion Pharmaceuticals, Inc. an oncology-focused company today announced the completion of a Type B End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) to [...]

KY Innovation, the state’s entrepreneurship and innovation enterprise, recently launched a new website

May 31st, 2019|0 Comments

KY Innovation, the state’s entrepreneurship and innovation enterprise, recently launched a new website. Bexion is honored to be chosen as the model business at the intersection of innovation and public good. Please click on the [...]

Robert G. Savage Added to Bexion’s Board of Directors

May 23rd, 2019|0 Comments

FOR IMMEDIATE RELEASE Covington, KY ~ 23 May 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today that the company has added Bob Savage, MBA to its Board of Directors. Robert G. Savage Mr. Savage brings to [...]

Bexion Pharmaceuticals is developing innovative cures for cancer.

Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.

Read More About Bexion
Clinical Trials

Clinical Trials

In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).

Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857